Lorena Picori

Dr. Lorena Picori

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
DDDavide Donner
Davide Donner
Paola FeracoPaola Feraco
Paola Feraco
LMLinda Meneghello
Linda Meneghello
BRBarbara Rombi
Barbara Rombi
LPLorena Picori
Lorena Picori
FCFranca Chierichetti
Franca Chierichetti
Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood. Despite clinical advances, subsets of these patients continue to suffer high morbidity and mortality rates associated with their disease. Following the European guidelines for 18F-FDG PET and PET-CT imaging in pediatric oncology, the routine use of 18F-FDG PET-CT may be useful for patients affected by rhabdomyosarcoma, in staging, in the evaluation of response to therapy, and for restaging/detection of relapse. The European Pediatric Protocols are very old, and for staging and restaging, they recommend only radionuclide bone scan. The 18F-FDG PET-CT exam is listed as an optional investigation prescribed according to local availability and local protocols in the investigations panel required at the end of the treatment. We present two cases highlighting the usefulness of 18F-FDG PET-CT in managing pediatric patients affected by rhabdomyosarcoma, providing some bibliographic references.

5 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Paola FeracoPaola Feraco
Paola Feraco
RFRossana Franciosi
Rossana Franciosi
LPLorena Picori
Lorena Picori
FSFederica Scalorbi
Federica Scalorbi
Cesare GagliardoCesare Gagliardo
Cesare Gagliardo
The introduction of molecular criteria into the classification of diffuse gliomas has added interesting practical implications to glioma management. This has created a new clinical need for correlating imaging characteristics with glioma genotypes, also known as radiogenomics or imaging genomics. Although many studies have primarily focused on the use of advanced magnetic resonance imaging (MRI) techniques for radiogenomics purposes, conventional MRI sequences remain the reference point in the study and characterization of brain tumors. A summary of the conventional imaging features of glioma molecular subtypes should be useful as a tool for daily diagnostic brain tumor management. Hence, this article aims to summarize the conventional MRI features of glioma molecular subtypes in light of the recent literature.

15 September 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Paola FeracoPaola Feraco
Paola Feraco
DSDaniele Scartoni
Daniele Scartoni
GPGiulia Porretti
Giulia Porretti
RPRiccardo Pertile
Riccardo Pertile
DDDavide Donner
Davide Donner
Dante AmelioDante Amelio
Dante Amelio
Objective: a considerable subgroup of meningiomas (MN) exhibit indolent and insidious growth. Strategies to detect earlier treatment responses based on tumour biology rather than on size can be useful. We aimed to characterize therapy-induced changes in the apparent diffusion coefficient (ADC) of MN treated with proton-therapy (PT), determining whether the pre- and early post-treatment ADC values may predict tumour response. Methods: Forty-four subjects with MN treated with PT were retrospectively enrolled. All patients underwent conventional magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) at baseline and each 3 months for a follow-up period up to 36 months after the beginning of PT. Mean relative ADC (rADCm) values of 46 MN were measured at each exam. The volume variation percentage (VV) for each MN was calculated. The Wilcoxon test was used to assess the differences in rADCm values between pre-treatment and post-treatment exams. Patients were grouped in terms of VV (threshold −20%). A p < 0.05 was considered statistically significant for all the tests. Results: A significant progressive increase of rADCm values was detected at each time point when compared to baseline rADCm (p < 0.05). Subjects that showed higher pre-treatment rADCm values had no significant volume changes or showed volume increase, while subjects that showed a VV < −20% had significantly lower pre-treatment rADCm values. Higher and earlier rADCm increases (3 months) are related to greater volume reduction. Conclusion: In MN treated with PT, pre-treatment rADCm values and longitudinal rADCm changes may predict treatment response.

24 July 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DSD. Scartoni
D. Scartoni
IGI. Giacomelli
I. Giacomelli
Sabina VennariniSabina Vennarini
Sabina Vennarini
Paola FeracoPaola Feraco
Paola Feraco
LPLorena Picori
Lorena Picori
DAD. Amelio
D. Amelio